Difference in the Estimation of Prognosis
What is the Difference in the Estimation of Prognosis of Advanced Cancer Patients Between Medical Oncologist, Gynecological Oncologists, and Palliative Care Physicians?
Objectives:
Primary Objective:
The primary objective is to identify the difference in the estimation of prognosis of advanced cancer patients between medical oncologists, gynecological oncologists, and palliative care physicians
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Medical oncologists or gynecological who referred patients to the palliative care team; Palliative Care physicians to whom the patients were referred; Patients with locally advanced, metastatic, or, not curable cancer.
- 18 years old or older
Exclusion Criteria:
N/A
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Medical Oncology Physicians
Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
|
Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis.
Survey will take approximately 5 minutes to complete.
Other Names:
|
|
Palliative Care Physicians
Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
|
Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis.
Survey will take approximately 5 minutes to complete.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimation of Patient Overall Survival by Oncologists and by Palliative Care Physicians per Estimation of Prognosis Questionnaire
Time Frame: 6 weeks
|
The answer to the question #4, "How long do you think this patient will live?" in the questionnaire is the primary endpoint. Denoting the oncologist estimated OS time from the day of palliative care consult to death by TOnc, palliative care physician estimate by TPalliative, and the true OS time by T0, we define the accuracy of the estimation of OS by oncologists and by palliative care physician as ΔOnc = TOnc - T0 ΔPalliative = TPalliative - T0. And the difference between these two estimates is calculated as ΔOS = ΔOnc - ΔPalliative. Based on the above formulas, ΔOS is actually calculated as (TOnc- TPalliative). The true survival time, T0, is cancelled out by the subtraction. |
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Angelique N. Wong, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016-0879
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasms of Independent (Primary) Multiple Sites
-
NCT03177681WithdrawnMalignant Neoplasms of Independent (Primary) Multiple Sites
-
NCT02911064Active, not recruitingMalignant Neoplasms of Independent (Primary) Multiple Sites | Benign Neoplasms
-
NCT02957565CompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple Sites
-
NCT03168763CompletedMalignant Neoplasms of Independent (Primary) Multiple Sites
-
NCT03042884CompletedMalignant Neoplasms of Independent (Primary) Multiple Sites | Benign Neoplasms | In Situ Neoplasms
-
NCT03035448CompletedMalignant Neoplasms of Independent (Primary) Multiple Sites
-
NCT03043378CompletedMalignant Neoplasms of Independent (Primary) Multiple Sites
-
NCT03435952Active, not recruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms of Mesothelial and Soft Tissue | Malignant Neoplasms of Thyroid and Other Endocrine Glands | Malignant Neoplasms of Urinary Tract | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs
-
NCT02915172WithdrawnAdvanced Cancer | Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms of Mesothelial and Soft Tissue | Malignant Neoplasms of Thyroid and Other Endocrine Glands | Malignant Neoplasms of Urinary Tract | Malignant Neoplasms of Digestive Organs
-
NCT03093909RecruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Melanoma and Other Malignant Neoplasms of Skin | Malignant Neoplasm of Bone and Articular Cartilage | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasm of Male Genital Organs | Malignant Neoplasms of Mesothelial and Soft Tissue | Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | Malignant Neoplasms of Thyroid and Other Endocrine Glands | Malignant Neoplasms of Urinary Tract
Clinical Trials on Estimation of Prognosis Questionnaire
-
NCT03874546Completed
-
NCT02503046CompletedRheumatoid Arthritis | Chronic Periodontitis
-
NCT06563401RecruitingType 1 Diabetes | Type 2 Diabetes
-
NCT07433751Not yet recruiting
-
NCT07228676CompletedRespiratory Insufficiency | Dyspnea | Work of Breathing | Oxygen
-
NCT03546699Active, not recruitingRespiratory Failure | ARDS | Lung Ultrasound
-
NCT05606809Recruiting
-
NCT04167891Completed